Hong Kong authorities indicated this weekend that they have placed a deposit for vaccines developed by Oxford University on August 31 through the World Health Organization, which looks to support the worldwide development and equitable distribution of a possible vaccine.
Russian Federation was in close dialogue with the Indian government and the leading drug manufactures of India regarding the localization of production of Sputnik V vaccine in India.
Bharat Biotech has received the drug regulator's clearance to move its vaccine candidate against Covid-19, Covaxin, to the second phase of human testing, The Sunday Express has learnt.
Sputnik V was developed by Moscow's Gamaleya Institute, which faced criticism after researchers and directors injected themselves with the prototype months ago, bypassing the usual process of initiating human trials. The data has been shared and is being evaluated by Indian experts.
Country President of AstraZeneca Australia & New Zealand, Liz Chatwin, said in a statement on Monday that "Further to our agreement with Government, we have finalised arrangements with CSL to manufacture approximately 30 million doses of AZD1222 in Australia, in addition to 3.8 million doses sourced from overseas".
Speaking on the move, Zhang Yuntao, Vice President, CNBG, said that apart from the active involvement from almost 10 countries in its Phase 3 clinical studies, the company has also received an overwhelming response from various other foreign countries, with cumulative orders racking up to 500 million doses of its vaccines. As reported, the trials have already started in United Arab Emirates, Bahrain, Peru, Argentina, Morocco, and Jordan. These trials on 375 volunteers are still continuing.
It was found that the vaccine is "safe, well-tolerated, and does not cause serious adverse events in healthy adult volunteers". But she noted that 7.5 billion people on the planet will need to be inoculated, and the number of vaccines may be double that figure if two doses are needed.